StockData

Accendra Health vs ScanSource

ACH and SCSC side by side, both in professional and commercial equipment and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACH and SCSC compare

ScanSource is the larger company, worth 59 times as much as Accendra Health ($1.2B against $19.5M).

ScanSource grew revenue faster over the last twelve months (6.1% versus −3.3% for Accendra Health).

ScanSource keeps more of each dollar of sales as profit, with a net margin of 2.4% compared with −11.4% at Accendra Health.

ScanSource scores higher on the StockData Score (14 against 4 for Accendra Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACHSCSC
Size and price
Market cap$19.5M$1.2B
Share price$0.254$57.71
Change, 1 year−95.1%37.4%
Change, 5 years−99.4%45.2%
Beta (5Y)1.461.09
Employees6,5002,100
StockData Score
Total score414 (better)
Valuation score4 (better)3
Growth score02 (better)
Performance score03 (better)
Health score06 (better)
Dividend score00
Valuation
P/E–15.9×
P/S0.0× (better)0.4×
P/B–1.3×
EV/EBITDA6.1× (better)9.6×
P/FCF–10.2×
PEG–16.99
FCF yield−1827%9.8% (better)
Fair value$12.26$64.31
Margin of safety97.9% (better)10.3%
Growth
Revenue growth (TTM)−3.3%6.1% (better)
Revenue growth, 5Y average−20.1%0.47% (better)
Net income growth (TTM)–10.2%
EPS growth (TTM)–21.3%
EPS growth, 5Y average–54.0%
Profitability
Gross margin44.8% (better)13.6%
Operating margin1.1%3.1% (better)
Net margin−11.4%2.4% (better)
FCF margin−13.5%3.5% (better)
Return on equity–8.7%
Return on invested capital1.6%8.1% (better)
Financial health
Debt / equity–0.11
Net debt / EBITDA5.990.11 (better)
Interest coverage0.2×15.0× (better)
Current ratio0.411.76 (better)
Altman Z-score0.303.66 (better)
Piotroski F-score28 (better)
Dividends and buybacks
Buyback yield–8.4%
Shareholder yield0.00%8.4% (better)
Ownership
Held by institutions81.1%107%
Held by insiders21.0%3.1%
Insider net buying, 12 months–−$7.2M
Short interest, % of float13.9%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.